GSK China Executive, Office Probe Subjects By Changsha Authority
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline (China) Investment is under investigation by local authorities in Changsha, China for "suspicion of economic crimes" of an unnamed high-level executive.